Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
07/2003
07/02/2003EP1322769A2 Protein phosphatases
07/02/2003EP1322762A2 Haemophilus influenzae antigens and corresponding dna fragments
07/02/2003EP1322760A2 G-protein coupled receptors
07/02/2003EP1322752A2 Fad4, fad5, fad5-2, and fad6, fatty acid desaturase family members and uses thereof
07/02/2003EP1322642A2 sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES
07/02/2003EP1322641A1 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases
07/02/2003EP1322636A1 Farnesyl transferase inhibiting 6- (substituted phenyl)methyl]-quinoline and quinazoline derivatives
07/02/2003EP1322631A2 Methods of providing and using compounds ( retinoids ) having activity as inhibitors of cytochrome p450rai
07/02/2003EP1322623A2 Hydroxy acid integrin antagonists
07/02/2003EP1322617A1 Compounds and methods for modulation of estrogen receptors
07/02/2003EP1322611A1 Chemical compounds
07/02/2003EP1322598A1 Nitroso diphenylamine derivatives
07/02/2003EP1322596A1 Zwitterionic tachykinin receptor antagonists
07/02/2003EP1322336A1 Method of increasing testosterone and related steroid concentrations in women
07/02/2003EP1322319A1 Use of il-8 protein modulators in the treatment of viral infections
07/02/2003EP1322316A1 Diuretic or sulphonylurea for use in antiviral treatment
07/02/2003EP1322312A1 Use of medicaments
07/02/2003EP1322310A1 Alpha v integrin receptor antagonists
07/02/2003EP1224180B1 Substituted azoles
07/02/2003EP1150666A4 Stimulating neutrophil function to treat inflammatory bowel disease
07/02/2003EP1140861B1 Novel polyhydroxypyrazine derivatives, preparation and pharmaceutical compositions containing same
07/02/2003EP1045849B1 Purine derivatives having phosphodiesterase iv inhibition activity
07/02/2003EP0900211B1 Thiadiazolyl(thio)ureas useful as matrix metalloprotease inhibitors
07/02/2003CN1427881A Low ionic strength ophthalmic compositions
07/02/2003CN1427837A Ortho-substituted anthranilic acid amides and their use as medicaments
07/02/2003CN1427726A Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
07/02/2003CN1113059C Pipeazino derivatives as neurokinin antagonists
07/02/2003CN1112918C Ophthalmic composition with decreased viscosity
07/01/2003US6586623 Thiol-based NAALADase inhibitors
07/01/2003US6586582 Human GABA receptor proteins and polynucleotides encoding the same
07/01/2003US6586474 Amidino compounds useful as nitric oxide synthase inhibitors
07/01/2003US6586471 Halogenated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
07/01/2003US6586456 Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide
07/01/2003US6586445 Racemic mixtures of 1,2,3,4-tetra hydro-1-(4-methoxyphenyl)-3 -(4-phenyl-1H-imidazol-2-yl)-9H- pyrido(3,4-b)indole, which bind to somatostatin receptors and block sodium channel modulators; antidiabetic, antiinflammatory agents; diarrhea
07/01/2003US6586442 Benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them
07/01/2003US6586424 Anticancer agents; anticholesterol agents
07/01/2003US6586423 Tyrosine kinase inhibitors
07/01/2003US6586422 Pyrazine and triazine derivatives of 1,2,4,5-tetrahydro-Benzo or Thieno [d] azepine
07/01/2003US6585995 Administering to a subject to inhibit a vaso-occlusive event an agent that reduces platelet counts in the subject in an amount effective to reduce platelet count in the subject to at least a low normal level
06/2003
06/26/2003WO2003052089A1 Disruption of the glutathione s-transferase-omega-1 gene
06/26/2003WO2003052048A2 Nucleic acid-associated proteins
06/26/2003WO2003051917A2 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
06/26/2003WO2003051890A1 Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides
06/26/2003WO2003051878A1 Quinolinones as prostaglandin receptor ligands
06/26/2003WO2003051868A1 Lactams as tachykinin antagonists
06/26/2003WO2003051842A2 Compositions decreasing activity of hormone-sensitive lipase
06/26/2003WO2003051841A2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
06/26/2003WO2003051840A1 Pyrrolidine and piperidine derivates as nk1 antagonists
06/26/2003WO2003051819A1 Substituted 1,5-diaminopentan-3-ol compounds
06/26/2003WO2003051458A1 Superoxide dismutase mimics for the treatment of ocular disorders and diseases
06/26/2003WO2003051400A1 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
06/26/2003WO2003051385A1 Pharmaceutical formulation comprising cyclosporin and use thereof
06/26/2003WO2003051369A1 Pharmaceutical containing n, n'-disubstituted piperazine compounds
06/26/2003WO2003051365A2 Use of compounds of the benzamide family as immunosuppressant
06/26/2003WO2003051352A1 Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
06/26/2003WO2003051351A1 Ophthalmic rofecoxib suspension for the treatment of ocular pain and inflammation
06/26/2003WO2003051333A1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
06/26/2003WO2003051313A2 Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
06/26/2003WO2003051277A2 Novel compounds
06/26/2003WO2002094202A3 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
06/26/2003WO2002060340A3 Method for identifying maxi-k channel blockers
06/26/2003WO2002046385A3 Enzymes
06/26/2003US20030120080 Such as (2S)-2-((4S)-4-(2,2-difluorovinyl)-2-oxopyrrolidinyl) butanamide; antiepileptic agents; anticonvulsants
06/26/2003US20030120079 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction
06/26/2003US20030119903 Use of trimebutine for treating pain
06/26/2003US20030119842 Salts of bicyclic, N-acylated imidazo-3-amines and imidazo-5-amines
06/26/2003US20030119835 Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents
06/26/2003US20030119832 Treatment of ocular disorders
06/26/2003US20030119811 Ion channel antagonists that are NMDA antagonists; treatment of migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke.
06/26/2003US20030119804 Otic microbial combination for treatment of animals with ruptured tympanic membrane
06/26/2003US20030119788 N-cyanomethyl carbonamides and sulfonamides which are cysteine protease, particularly cathepsin K, inhibitors
06/26/2003US20030119684 Conditioning solution for contact lenses and a method of using the same
06/26/2003US20030119111 G-protein coupled receptor, named 2871 receptor
06/26/2003US20030119095 Novel nucleic acid sequences encoding human vesicle transport protein-like and residue rat-like polypeptides
06/26/2003US20030119076 B7-like polynucleotides, polypeptides, and antibodies
06/26/2003US20030118657 Treatment of disease states characterized by excessive or inappropriate angiogenesis
06/26/2003US20030118602 Peptides and immunologically functional variants thereof which are immunogenic epitopes recognized by CD8+ class I major histocompatibility complex restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus infection
06/26/2003US20030118576 Administering to a human or an animal a therapeutically amount of coenzyme Q10 or a derivative, effective to treat or prevent apoptotic events occurring in ocular degenerative pathologies of posterior part of the eye
06/26/2003US20030118575 Administering a pyrazole compound containing urea or thiourea groups, twice daily to a patient in need of treatment of a cytokine mediated disease
06/26/2003US20030118528 Topical delivery of codrugs
06/26/2003CA2471777A1 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
06/26/2003CA2471589A1 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
06/26/2003CA2471500A1 Substituted 1,5-diaminopentan-3-ol compounds
06/26/2003CA2470236A1 Lactams as tachykinin antagonists
06/26/2003CA2469944A1 Medicaments comprising n, n'-disubstituted piperazine compounds and their use
06/26/2003CA2469663A1 Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
06/26/2003CA2469048A1 Quinolinones as prostaglandin receptor ligands
06/26/2003CA2468413A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
06/26/2003CA2446292A1 Nucleic acid-associated proteins
06/25/2003EP1321144A1 Eye drops
06/25/2003EP1321138A1 Coenzyme Q10 for the treatment of ocular diseases
06/25/2003EP1320614A2 Novel proteases
06/25/2003EP1320603A1 Uses of the gjb6 gene for treating certain types of alopecia including the clouston's syndrome, and for screening compounds capable of being efficient in the treatment of alopecia with genetic susceptibility
06/25/2003EP1320600A1 Transporters and ion channels
06/25/2003EP1320589A2 Antiangiogenic polypeptides and methods for inhibiting angiogenesis
06/25/2003EP1320550A2 G-protein coupled receptors
06/25/2003EP1320548A2 Transporters and ion channels
06/25/2003EP1320545A2 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen
06/25/2003EP1320530A1 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
06/25/2003EP1320523A2 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
1 ... 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 ... 531